bioRxivMicrobiology
Development of a novel glycoengineering platform for the rapid production of conjugate vaccines.
S. Abouelhadid, E. Atkins, E. Kay, I. Passmore, S. J. North, B. Lehri, P. Hitchen, E. Bakke, M. Rahman, J. Bosse, Y. Li, V. S. Terra, P. Langford, A. Dell, B. W. Wren, J. Cuccui
Abstract
Antimicrobial resistance (AMR) is threatening the lives of millions worldwide. Antibiotics which once saved countless lives, are now failing, ushering in vaccines development as a current global imperative. Conjugate vaccines produced either by chemical synthesis or biologically in Escherichia coli cells, have been demonstrated to be safe and efficacious in protection against several deadly bacterial diseases. However, conjugate vaccines assembly and production have several shortcomings which hinders their wider availability. Here, we developed a tool, Mobile-element Assisted Glycoconjugation by Insertion on Chromosome, MAGIC, a novel method that overcomes the limitations of the current conjugate vaccine design method(s). We demonstrate at least 2-fold increase in glycoconjugate yield via MAGIC when compared to conventional bioconjugate method(s). Furthermore, the modularity of the MAGIC platform also allowed us to perform glycoengineering in genetically intractable bacterial species other than E. coli. The MAGIC system promises a rapid, robust and versatile method to develop vaccines against bacteria, especially AMR pathogens, and could be applied for biopreparedness.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Bacterial glycoengineering as a biosynthetic route to customized glycomolecules
Laura E. Yates, Dominic C. Mills, Matthew P. DeLisa·Advances in biochemical engineering, biotechnologyPeer-reviewed·Jan 1, 2018
- On-demand, cell-free biomanufacturing of conjugate vaccines at the point-of-care
Jessica C. Stark, Thapakorn Jaroentomeechai, … Michael C. Jewett·Science AdvancesPeer-reviewed·Feb 3, 2021
- A scalable cell-free manufacturing platform for two-step bioproduction of immunogenic conjugate vaccines
Derek A. Wong, Rochelle Aw, … Michael C. Jewett·ACS Synthetic BiologyPeer-reviewed·Nov 19, 2025
- A low-cost recombinant glycoconjugate vaccine confers immunogenicity and protection against enterotoxigenic Escherichia coli infections in mice
Asher J. Williams, Katherine F. Warfel, … Matthew P. DeLisa·Frontiers in Molecular BiosciencesPeer-reviewed·Mar 2, 2023
- A platform for the recombinant production of Group A Streptococcus glycoconjugate vaccines
S. Ajay Castro, I. J. Passmore, … H. C. Dorfmueller·bioRxiv·Mar 1, 2024
- Development and evaluation of a dual target glycoconjugate vaccine against Shigella sonnei
Catherine L. Hall, Tom Flood, … Brendan William Wren·bioRxiv·Mar 26, 2026